←
Marco Moschini788 posts
Marco Moschini avatar✓

Marco Moschini ✓

@UroMoschini

MD PhD FEBU, Urologist, Milano, Italy. @EAUYAUrology Urothelial Carcinoma Group

◷ Joined July 2013▧ 126 Photos and videos
Ashish M. Kamat, MD, MBBS avatar
⟳ Marco Moschini retweeted
Ashish M. Kamat, MD, MBBS@UroDocAsh·Aug 6

Just released in @NatRevUrol : Integrating clinically actionable biomarkers into bladder cancer care : recommendations from the International Bladder Cancer Group @IBCG_BladderCA During our deliberations, one theme was clear: biomarkers don't improve care simply because they're "novel or new" They improve care when they're validated, reproducible, and actually change clinical decisions 🧵 @pjhensley11 @jteoh_hk @UrogerliMD @shilpaonc @LauraBukavinaMD @mouwlab @AndreaNecchi @niyatilobo @Agarwal_CaB @LiangChengMD @karima_oualla @drtanws @MaxKates @BrigidaMaiorano @h_alahmadie @TomFlaigMD @AmirHorowitz @WesKassouf @djmcconkey @JanetKukreja @LAUrology_NL @carme_mir1 @UroMoschini @BogdanaSchmidt @VigneshPackiam

Post attachment
European Urology avatar
⟳ Marco Moschini retweeted
European Urology@EUplatinum·Aug 1

🎉 Congratulations to our August Reviewer of the Month, Dr. Marco Moschini! Your commitment to the Platinum Journal keeps us a cut above the rest. Thank you! #EURUROL #ROTM #Urology

Post attachment
SIU-Urology avatar
⟳ Marco Moschini retweeted
SIU-Urology@SIU_urology·Feb 12

🔬✨ Discover the surgical innovations reshaping bladder cancer care on a new Global Perspectives webinar on SIU Academy! Join top global experts for this informative session on cutting-edge resection techniques, robotic & open radical cystectomy, and real-world strategies to improve outcomes in MIBC. Watch open access on SIU Academy: bit.ly/3Z3sInF @fkorkes @jteoh_hk @UroMoschini @SimonemorraMD

Post attachment
Julian Chavarriaga avatar
⟳ Marco Moschini retweeted
Julian Chavarriaga@chavarriagaj·18 Oct 2025

📢 New SOC for MIBC #ESMO25 Dr. Christof Vulsteke presents KEYNOTE-905: 🚫 No cisplatin? No problem. EV+pembro delivers. 👥 n=344 cis-ineligible MIBC (80% renal impairment, 15% ECOG 2) 🔹 EFS HR 0.40 | OS HR 0.50 🔹 pCR: 57.1% vs 8.6% (ITT, non-op = non-responders) 🔹 No ↑ surgical complications ✅ 1st phase 3 trial showing OS benefit in this population| Unprecedented pCR↑ @urotoday @myESMO

Post attachmentPost attachmentPost attachmentPost attachment
MolinetteUrology avatar
⟳ Marco Moschini retweeted
MolinetteUrology@UroMolinette·19 Sep 2025

The Urothelial Cancer Update 2025 is officially underway. Esteemed experts are on stage sharing the latest advancements in diagnosis and treatment. ​What has been the most impactful session for you so far? Let us know in the comments! 👇 @cittasalute_to @unito @UroMolinette

Post attachmentPost attachment
0:04
0:04
Ashish M. Kamat, MD, MBBS avatar
⟳ Marco Moschini retweeted
Ashish M. Kamat, MD, MBBS@UroDocAsh·20 Aug 2025

Thrilled to welcome over 100 global experts and patient advocates to Houston for #IBCG25! Together we’ll focus on two crucial goals: integrating bladder cancer biomarkers into clinical practice, and developing tools to better monitor and address local bladder toxicity - guided by the patient voice. Both topics reflect our @IBCG_BladderCA mission: to create real-world solutions that improve outcomes and provide practical tools for patients worldwide; through collaboration, collaboration and ... more collaboration! @shilpaonc @UrogerliMD @pjhensley11 @BladderCancerUS @WorldBladderCan @AndreaNecchi @PGrivasMDPhD @siadaneshmand @bbmdmsk @MaxKates @VigneshPackiam @LauraBukavinaMD @drtanws @niyatilobo @MarekBabjuk @joanfundi @RobertoContieri @mouwlab @OAlhalabiMD @urotoday @WesKassouf @SimaPorten @UroMoschini @LAUrology_NL @AStenzl @Agarwal_CaB @marigfern @spsutkaMD @jteoh_hk @Heer_Lab @SpiessPhilippe @SWilliams_MD @achoud72 @paolo_gontero @JanetKukreja @BenjaminPradere @GustavoVillold4 @TomFlaigMD @DrByronLee @KKBree @gautiermarcq @LiangChengMD @h_alahmadie @djmcconkey @BogdanaSchmidt @bkonety

Post attachmentPost attachment